Olema Oncology – Investigational Compound for ER+ / HER2- Breast Cancer

Sean Bohen, M.D., Ph.D., is President and CEO of Olema Oncology, a company committed to improving outcomes for women living with cancer. Dr. Bohen discusses Olema’s lead investigational asset, OP-1250, now in Phase 2 clinical development for women with recurrent, locally advanced, or metastatic ER+/HER2- breast cancer. The initial data from Olema’s Phase 1 studies provide proof-of-concept supporting OP-1250’s potential as a once-daily oral therapy with attractive pharmacokinetics, favorable tolerability, and anti-tumor activity both as a monotherapy or in combination with current treatments.

Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.

Liked it? Take a second to support healthprofessionalradio on Patreon!
Become a patron at Patreon!


Leave a Reply

You must be logged in to post a comment.